May 15, 2020
FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
Dec 10, 2019
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019
Nov 26, 2019
How FDA and Oncology Industry are Making Joint Efforts to Utilize Accelerated Approval Pathways for Cancer Drugs
Oct 29, 2019
Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars
Oct 15, 2019
Health Canada Approves Ipsen's CABOMETYX(TM) (cabozantinib) for the First-Line Treatment of Adults with Advanced Renal Cell Carcinoma
Sep 26, 2019
Currax(TM) Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®
Mar 12, 2019
Secura Bio Acquires Global Rights To Farydak®
Mar 06, 2019
Water Street's Partnership with Leading Medical Products Company Leads to FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide
Feb 19, 2019
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
Feb 16, 2019
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Feb 11, 2019
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Feb 07, 2019
CStone and IMPACT Therapeutics' clinical collaboration progresses to IND filing acceptance for CS1001+IMP4297 combination therapy
Dec 06, 2018
Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies
Dec 04, 2018
Explosion of Latest Clinical Studies and Results Reinvigorating Immunotherapy Market
Nov 15, 2018
Key Pancreatic Cancer Therapy Developments Crucial in Combating World's Toughest Cancer
Oct 09, 2018
Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress
Aug 09, 2018
Sierra Oncology Reports Second Quarter Results
Jan 17, 2018
Bayer to Highlight New Research at ASCO GI 2018 Cancer Symposium
Nov 15, 2017
Promius Pharma Announces ZEMBRACE® SymTouch® (Sumatriptan Injection) 3 mg Achieves Primary Endpoint in Post-Approval Clinical Trial
Nov 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRa Genotypes